Browse by category

Viking’s dual GLP-1/GIP Receptor Agonist VK2735 shows 14.7% reduction in mean body weight from baseline at 13 weeks

Outcomes from Viking Therapeutics’ Phase 2 VENTURE clinical trial of VK2735 - a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors – reveal that after 13 weekly subcutaneous doses, participants receiving VK2735 demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7% with no signs of plateau. The outcomes highlights the previously reported positive results from th

First patients randomised in KaiNETIC Global Phase 3 Clinical Program of ribupatide

3 hours ago

Viking’s dual GLP-1/GIP Receptor Agonist VK2735 shows 14.7% reduction in mean body weight from baseline at 13 weeks

2 days ago

Weight loss drugs and surgery improve fat-to-muscle ratio in obesity

3 days ago

Browse by category

Viking’s dual GLP-1/GIP Receptor Agonist VK2735 shows 14.7% reduction in mean body weight from baseline at 13 weeks

Browse by tag

First patients randomised in KaiNETIC Global Phase 3 Clinical Program of ribupatide

Viking’s dual GLP-1/GIP Receptor Agonist VK2735 shows 14.7% reduction in mean body weight from baseline at 13 weeks

Weight loss drugs and surgery improve fat-to-muscle ratio in obesity

Back to Top